ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-STEAP1 Antibody-drug Conjugate ADRX-0405

Its studies are led by Adcentrx Therapeutics.

Furthest: phase 1, since Nov 26, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Adcentrx Therapeutics11 open or runningphase 1since Nov 26, 2024Nov 26, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2024First study: phase 1 study in Solid TumorsFirst studyNCT06710379 · 68 planned · United States

TargetBeta

STEAP1 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) ”NCIt, by rule

Other programs on STEAP1

ProgramCompanyFurthest phaseStudies
xaluritamigruleAmgenphase 37
Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969AbbViephase 11
HLX3902Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06710379Solid Tumors · United States1RecruitingJul 202668

How it is read

Names in the registry

  • “ADRX-0405”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.